ARTICLE | Company News
Alector, AbbVie in Alzheimer’s deal
October 24, 2017 11:33 AM UTC
Alector LLC (San Francisco, Calif.) and AbbVie Inc. (NYSE:ABBV) partnered to discover and develop immuno-neurology therapies against undisclosed targets to treat Alzheimer's disease.
Alector will receive $205 million up front and an AbbVie investment of up to $20 million...